Tumor News and Research

RSS

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Tiny gold particles can help doctors detect tumor cells circulating in the blood of patients with head and neck cancer, researchers at Emory and Georgia Tech have found.

14 Feb 2011

Genetic map for prostate cancer

Researchers have managed to uncover the whole genetic sequence in prostate cancer. This complete map, hope researchers, will eventually lead to the development of more targeted drugs and a better understanding of which prostate cancers are likely to spread, one of the biggest challenges for physicians and patients.

13 Feb 2011

Guide star and time-reversal mirror in biomedical imaging

Astronomers have a neat trick they sometimes use to compensate for the turbulence of the atmosphere that blurs images made by ground-based telescopes. They create an artificial star called a guide star and use its twinkling to compensate for the atmospheric turbulence.

11 Feb 2011

Cancer cells 'addicted' to self-preservation process

A team of investigators at The Cancer Institute of New Jersey (CINJ); Rutgers, The State University of New Jersey; and Princeton University, have determined that cancer cells are "addicted" to a self-preservation process known as autophagy. They also showed that the inhibition of that process could prove to be a valuable treatment approach for aggressive cancers. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

11 Feb 2011

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

The Massachusetts General Hospital research team that first discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including retrotransposons - also called "jumping genes" - that copy and insert themselves into other areas of the genome.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

Indiana University creates Institute for Personalized Medicine

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Photodynamic therapy could be useful in eradicating tumor-associated lymphatic vessels

Tumor cells have several routes that enable them to move from the primary tumor to distant tissues, a process called metastasis. It is metastasis of the primary tumor that kills most cancer patients. One of the least studied routes of metastasis is the lymphatic system. Many tumors produce factors that promote the formation of new lymphatic vessels (lymphangiogenesis).

10 Feb 2011

Physicist creates technology that may enhance pharma industry's early drug discovery capabilities

A Purdue physicist has created technology to detect motion inside three-dimensional tumor spheroids, which may enhance the pharmaceutical industry's early drug discovery capabilities.

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients.

9 Feb 2011

Study finds breast cancer patients do not benefit from axillary lymph node dissection

Among patients with early-stage breast cancer that had spread to a nearby lymph node and who received treatment that included lumpectomy and radiation therapy, women who just had the sentinel lymph node removed did not have worse survival than women who had more extensive axillary lymph node dissection, according to a study in the February 9 issue of JAMA.

9 Feb 2011

LESSOnc technique promising new surgical option for certain liver cancers

Surgeons at UC San Diego Health System have identified a new application for "scarless" surgery tools that are normally used for natural orifice translumenal endoscopic surgery (NOTES).

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Allergies appear to reduce glioma risk

The more allergies one has, the lower the risk of developing low- and high-grade glioma, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

Tumor News and Research

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Genetic map for prostate cancer

Guide star and time-reversal mirror in biomedical imaging

Cancer cells 'addicted' to self-preservation process

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

Full genetic blueprint of multiple prostate tumors laid bare

Indiana University creates Institute for Personalized Medicine

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Photodynamic therapy could be useful in eradicating tumor-associated lymphatic vessels

Physicist creates technology that may enhance pharma industry's early drug discovery capabilities

Everolimus phase III study shows improved progression-free survival in patients with pNET

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

Study finds breast cancer patients do not benefit from axillary lymph node dissection

LESSOnc technique promising new surgical option for certain liver cancers

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Allergies appear to reduce glioma risk

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News